Skip to search formSkip to main contentSkip to account menu

garenoxacin

Known as: 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (3)

Anti-Bacterial AgentsFluoroquinolonesTopoisomerase II Inhibitors

Narrower (1)

BMS 284756
Garenoxacin MesylateGarenoxacin:Susc:Pt:Isolate:OrdQnGarenoxacin:Susc:Pt:Isolate:OrdQn:Agar diffusionGarenoxacin:Susc:Pt:Isolate:OrdQn:MIC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
2013
2013
A novel mutation in the transmembrane nonpore region of the KCNH2 gene causes severe clinical manifestations of long QT syndrome.
Highly Cited
2006
Highly Cited
2006
Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.
OBJECTIVES The aim of the present study was to determine correlation between bmeB efflux pump overexpression and resistance to… 
2004
2004
Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin
ABSTRACT Stepwise selection of ciprofloxacin-resistant Haemophilus influenzae mutants produced first-, second-, third-, and… 
Review
2003
Review
2003
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.
Highly Cited
2003
Highly Cited
2003
Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus
ABSTRACT The new quinolone garenoxacin (BMS-284756), which lacks a C-6 fluorine, was examined for its ability to block the growth… 
2003
2003
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.
The effects of garenoxacin (formerly T-3811 or BMS-284756) on the central nervous system (CNS) were compared with various… 
2003
2003
Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases
ABSTRACT The activity of garenoxacin was assessed against 412 Streptococcus pneumoniae isolates (49.3% from the adult population… 
2003
2003
Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci
ABSTRACT The emergence of multidrug-resistant strains of Streptococcus pneumoniae drives the development and evaluation of new… 
2002
2002
Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs.
The articular toxicity of garenoxacin (formerly T-3811 or BMS-284756) was experimentally examined utilizing juvenile beagle dogs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)